Exploiting AT2R to Improve CD117 Stem Cell Function In Vitro and In Vivo--Perspectives for Cardiac Stem Cell Therapy.
CD117(+) stem cell (SC) based therapy is considered an alternative therapeutic option for terminal heart disease. However, controversies exist on the effects of CD117(+) SC implantation. In particular, the link between CD117(+) SC function and angiotensin-II-type-2 receptor (AT2R) after MI is continuously discussed. We therefore asked whether 1) AT2R stimulation influences CD117(+) SC properties in vitro and, 2) which effects can be ascribed to AT2R stimulation in vivo. We approached AT2R stimulation with Angiotensin II while simultaneously blocking its opponent receptor AT1 with Losartan. CD117 effects were dissected using a 2D-Matrigel assay and HL-1 co-culture in vitro. A model of myocardial infarction, in which we implanted EGFP(+) CD117 SC, was further applied. While we found indications for AT2R driven vasculogenesis in vitro, co-culture experiments revealed that CD117(+) SC improve vitality of cardiomyocytes independently of AT2R function. Likewise, untreated CD117(+) SC had a positive effect on cardiac function and acted cardioprotective in vivo. Therefore, our data show that transient AT2R stimulation does not significantly add to the beneficial actions of CD117(+) SC in vivo. Yet, exploiting AT2R driven vasculogenis via an optimized AT2R stimulation protocol may become a promising tool for cardiac SC therapy.